4 years of RESONATE data for CLL patients treated with ibrutinib

Latest in relapsed and refractory multiple myeloma

Latest maintenance strategies in multiple myeloma

Front-line combinations in multiple myeloma: Highlights from EHA 2017

Lenalidomide with CD19 antibodies in L-MIND

The Myeloma XI trial - lenalidomide or thalidomide in triplet

Denosumab or zoledronic acid for bone disease in multiple myeloma

Hemcare - multiple myeloma learning programme

Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM

Enasidenib in mIDH relapsed and refractory AML

Impact of mutational profile at diagnosis for MDS/CML

Delayed infection exposure as a trigger for childhood ALL

Triplet therapy for all comers in the CLL-BAG trial

The role of patient advocates in trial design, participation

Disruption of BAFF-BCR crosstalk in CLL

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Blood thinners a risk with cancer-associated venous thromboembolism

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

ZUMA 1: CD19 CAR T cells for refractory NHL

Interim analysis of the JULIET study

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

400mg imatinib as good as 800mg for 10 year CML survival

Carfilzomib combinations in ENDEAVOR and FORTE

Deep molecular response to gilteritinib in CHRYSALIS trial

Dual JAK/SYK inhibition in refractory NHL with cerdulatinib

Diverse T lymphocyte population fights leukaemia more effectively

Delayed exposure to common infections causes acute childhood leukaemia

Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL